https://scholars.lib.ntu.edu.tw/handle/123456789/631847
標題: | Next-Generation Immunotherapy for Lymphoma & Leukemia from the Perspective in 2021 | 其他標題: | 從2021年看淋巴癌與血癌的次世代免疫療法 | 作者: | Hsin-Yu Lu Ting-Wei Lyu Shih-Hsun Lan Geng-Ning Hu Kuo-Jui Sun WAN-HSUAN LEE Min Yen Lo TAI-CHUNG HUANG |
關鍵字: | Lymphoma;leukemia;immunotherapy | 公開日期: | 1-十月-2021 | 卷: | 32 | 期: | 5 | 起(迄)頁: | 342 | 來源出版物: | Journal of Internal Medicine of Taiwan | 摘要: | Immunotherapy has been revolutionizing the treatment of hematological malignancies including lymphoma and leukemia. A substantive subset of these patients was inflicted with relapsed or refractory disease that required intensive therapeutics such as high dose chemotherapy and hematopoietic stem cell transplantation. Eventually many of them still succumb to disease. Facing this conundrum now in 2021, hematologists are equipped with more powerful therapeutics in armamentarium. To overcome immune escape of these recalcitrant neoplasms, three types of immunotherapy have gained foothold through vigorous clinical studies: immune checkpoint inhibitors, chimeric antigen receptor T cells and bispecific T cell engagers. Their efficacies are bringing new hopes to the field. |
URI: | https://www.airitilibrary.com/Publication/alDetailedMesh?docid=10167390-202110-202112020002-202112020002-342-348 https://scholars.lib.ntu.edu.tw/handle/123456789/631847 |
DOI: | 10.6314/JIMT.202110_32(5).05 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。